Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
Public ClinicalTrials.gov record NCT01286740. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2B Open Label Pilot Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV 1 Infected Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA \< 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.
Study identification
- NCT ID
- NCT01286740
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2011 (Type not available)
- Primary completion
- Jul 2011 (Actual)
- Completion
- Mar 2012 (Actual)
- Last update posted
- Apr 26, 2013
2011 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Living Hope Clinical Foundation | Long Beach | California | 90814 | — |
| Peter J. Ruane MD Inc | Los Angeles | California | 90036 | — |
| Anthony Mills MD, Inc. | Los Angeles | California | 90069 | — |
| La Playa Medical Group and Clinical Research | San Diego | California | 92103 | — |
| Dupont Circle Physicians Group, P.C. | Washington D.C. | District of Columbia | 20009 | — |
| Whitman Walker Clinic | Washington D.C. | District of Columbia | 20009 | — |
| Capital Medical Associates, PC | Washington D.C. | District of Columbia | 20036 | — |
| The Kinder Medical Group | Miami | Florida | 33133 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Atlanta ID Group | Atlanta | Georgia | 30309 | — |
| Infectious Disease Specialists of Atlanta | Decatur | Georgia | 30033 | — |
| Northstar Medical Center | Chicago | Illinois | 60657 | — |
| Community Research Initiative of New England | Boston | Massachusetts | 02215 | — |
| Be Well Medical Center, P.C. | Berkley | Michigan | 48072 | — |
| Southampton Healthcare, Inc. | St Louis | Missouri | 63139 | — |
| Southwest Infectious Disease Clinical Research, Inc. | Addison | Texas | 75001 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| Peter Shalit, M.D. | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01286740, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2013 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01286740 live on ClinicalTrials.gov.